Cloning, Expression, and Biochemical Characterization of Streptomyces rubellomurinus Genes Required for Biosynthesis of Antimalarial Compound FR900098  by Eliot, Andrew C. et al.
Chemistry & Biology
Brief CommunicationCloning,Expression,andBiochemicalCharacterization
of Streptomyces rubellomurinusGenes Required
for Biosynthesis of Antimalarial Compound FR900098
Andrew C. Eliot,1,5 Benjamin M. Griffin,2 Paul M. Thomas,2,3 Tyler W. Johannes,2,4 Neil L. Kelleher,2,3 Huimin Zhao,2,4
and William W. Metcalf1,2,*
1Department of Microbiology, University of Illinois, 601 South Goodwin Avenue, Urbana, IL 61801, USA
2Institute for Genomic Biology, University of Illinois, 1206 West Gregory, Urbana, IL 61801, USA
3Department of Chemistry
4Department of Chemical and Biomolecular Engineering
University of Illinois at Urbana-Champaign, 600 South Matthews Avenue, Urbana, IL 61801, USA
5Present address: DuPont Central Research and Development, Experimental Station E328/250A, Wilmington, DE 19880, USA
*Correspondence: metcalf@uiuc.edu
DOI 10.1016/j.chembiol.2008.07.010SUMMARY
The antibiotics fosmidomycin and FR900098 are
members of a unique class of phosphonic acid natu-
ral products that inhibit the nonmevalonate pathway
for isoprenoid biosynthesis. Both are potent antibac-
terial and antimalarial compounds, but despite their
efficacy, little is known regarding their biosynthesis.
Here we report the identification of the Streptomyces
rubellomurinus genes required for the biosynthesis
of FR900098. Expression of these genes in Strepto-
myces lividans results in production of FR900098,
demonstrating their role in synthesis of the antibiotic.
Analysis of the putative gene products suggests that
FR900098 is synthesized by metabolic reactions
analogous to portions of the tricarboxylic acid cycle.
These data greatly expand our knowledge of phos-
phonate biosynthesis and enable efforts to overpro-
duce this highly useful therapeutic agent.
INTRODUCTION
Afflicting an estimated 500million people and causing over 1mil-
lion deaths per year, malaria exacts a terrible toll in tropical and
subtropical regions (Snow et al., 2005). Although a number of an-
timalarial treatments exist, resistance is increasingly common,
creating an urgent need for new drugs (Schlitzer, 2007). Among
the most promising of such new antimalarial therapies are the
phosphonic acid antibiotics FR900098 and fosmidomycin
(Figure 1A).
These two compounds were originally identified as antibiotics
produced by Streptomyces rubellomurinus and Streptomyces
lavendulae, respectively (Okuhara et al., 1980). Subsequent
studies showed that both act as potent inhibitors of 1-deoxy-D-
xylulose 5-phosphate reductoisomerase (DXR), the first enzyme
in the nonmevalonate pathway for isoprenoid biosynthesis (Ku-
zuyama et al., 1998; Rohmer, 1999). The identification of this
pathway in the malaria-causing parasite Plasmodium falciparumChemistry & Biology 15, 7renewed interest in these phosphonate antibiotics as potential
antimalarial drugs (Jomaa et al., 1999). Both FR900098 and fos-
midomycin are effective againstP. falciparum in vitro and against
the closely related P. vinckei in mice (Jomaa et al., 1999). These
drugs are active even againstmultidrug-resistant strains ofP. fal-
ciparum (Jomaa et al., 1999).
Given the importance of this new class of antimalarial com-
pounds, we aimed to identify the FR900098 biosynthetic genes
from S. rubellomurinus. To date, complete biosynthetic gene
clusters have been identified for only three phosphonate com-
pounds: aminoethylphosphonate (Barry et al., 1988), fosfomycin
(Hidaka et al., 1995), and bialaphos (Blodgett et al., 2005;
Schwartz et al., 2004). These and other studies led to the pro-
posal that the initial step in all phosphonate biosyntheses is the
rearrangement of phosphoenolpyruvate (PEP) to form phospho-
nopyruvate, catalyzed by the enzyme PEP mutase (Seidel et al.,
1988; Figure 1B). Consistent with this idea, PEP mutase activity
was detected in cell-free extracts of S. rubellomurinus (Hidaka
et al., 1989). We therefore developed a PEP mutase gene-tar-
geted approach to identify the FR900098 biosynthetic genes,
which is reported here along with heterologous expression and
production of the antibiotic in S. lividans. These results provide
significant new insight into the biosynthesis of phosphonic acid
antibiotics and make possible efforts to enhance bioproduction
of this important antimalarial compound.
RESULTS AND DISCUSSION
A PCR-based strategy was used to clone the FR900098 biosyn-
thetic gene cluster. Based on the precedent of other phospho-
nate biosyntheses, we assumed that the initial step in
FR900098 biosynthesis is the PEP mutase-catalyzed rearrange-
ment to form phosphonopyruvate. Using degenerate primers
designed to anneal to conserved sequences within known PEP
mutase genes (Blodgett et al., 2005), we were able to amplify
a 406 bp fragment from S. rubellomurinus genomic DNA that en-
codes a peptide homologous to known PEPmutases. On the as-
sumption that the biosynthetic genes for FR900098 are clustered
on the chromosome, we constructed a large insert fosmid library
from S. rubellomurinus genomic DNA. PCR screening of the65–770, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 765
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FR900098 Biosynthesislibrary using PEP mutase-specific primers allowed identification
of four clones encoding the putative PEPmutase.We transferred
one of these clones (designated 4G7) to the chromosome of
Streptomyces lividans, a genetically tractable organism that is
not known to produce phosphonic acid compounds, in an at-
tempt to determine if fosmid 4G7 contained all the genes neces-
sary for production of FR900098. Production of FR900098 by the
recombinant S. lividans strain was confirmed by four lines of
evidence (Figure 2).
First, supernatant from cultures of S. lividans 4G7 inhibited pu-
rified E. coli DXR. This enzyme is the known target of the antibi-
otic (Kuzuyama et al., 1998) and can be completely inhibited by
concentrations of FR900098 as low as 100 nM (data not shown).
Supernatant from cultures of S. lividans 4G7 eliminated DXR ac-
tivity, whereas supernatant from cultures of the parent S. lividans
strain grown under the same conditions had no effect (Figure 2A).
Second, we developed a two-plate assay system utilizing an
engineered E. coli bioassay strain (see Supplemental Data avail-
able online) with an IPTG-inducible hypersensitivity to phospho-
nate antibiotics. In the presence of inducer, both authentic
FR900098 (50 mg/ml) and supernatant from S. lividans 4G7
produced substantial zones of inhibition, whereas the parent
S. lividans strain did not (Figure 2B).
Third, 31P-NMR spectroscopy of concentrated S. lividans 4G7
culture supernatant revealed a signal at25 ppm that was inten-
sified when authentic FR900098 was added to the sample. No
new signal was observed, indicating that the phosphonate spe-
cies in the supernatant is FR900098 or a closely related com-
pound (Figure 2C). No peaks are observed in this region of the
Figure 1. Phosphonic Acid Antibiotics and Their Biosynthesis
(A) The structures of the antimalarial compounds FR900098 and fosmidomy-
cin. Both inhibit DXR, an essential enzyme in the isoprenoid biosynthetic path-
way in malaria-causing parasites.
(B) The initial reactions in the biosynthesis of 2-aminoethylphosphonic acid,
fosfomycin, and bialaphos. In the first step, catalyzed by PEP mutase, phos-
phoenolpyruvate is rearranged to phosphonopyruvate, which is then decar-
boxylated to yield phosphonoacetaldehyde in a reaction catalyzed by phos-
phonopyruvate decarboxylase.766 Chemistry & Biology 15, 765–770, August 25, 2008 ª2008 Elsevspectrum in supernatant from cultures of the S. lividans parent
strain.
Fourth, the presence of FR900098 in the S. lividans 4G7 cul-
ture supernatant was further confirmed by coupled liquid
chromatography high-resolution mass spectrometry (LCMS)
(Figure 2D). In addition to FR900098, we detected N-acetyl-3-
aminophosphonate, suggesting that this compound may be an
intermediate in the synthesis of the antibiotic (Figure S1).
Fosmid 4G7 was sequenced using a transposon-based strat-
egy as described in the Supplemental Data. The mini-MuAE5
transposon used in this effort also allowed facile construction
of deletion subclones lacking the region between the site of
transposon insertion and the cloning junction with the fosmid
vector. We tested a series of progressively larger deletion
plasmids for their ability to confer FR900098 production upon
S. lividans, resulting in the identification of a minimal 11.3 kb
region required for antibiotic synthesis (Figure 3A).
Analysis of the minimal DNA sequence revealed eight open
reading frames (ORFs), which were designated frbA-H for
FR900098 biosynthesis, including the expected PEPmutase ho-
molog (frbD). In addition, two ORFs (designated frbI and frbJ) im-
mediately downstream of frbH appear to be part of the same op-
eron, although they are not required for successful antibiotic
production in S. lividans. Downstream of frbJ and separated
from it by a region containing a 38 bp inverted repeat is an
ORF that is homologous to the gene for DXR. We have desig-
nated this ORF dxrB. Possible functions of the Frb proteins
were assigned based on homology to proteins of known function
(Table S1).
The initial step in FR900098 biosynthesis is presumed to be
the PEP mutase-catalyzed formation of phosphonopyruvate,
a highly unfavorable reaction (equilibrium is R 500:1 in favor of
PEP) (Bowman et al., 1990). In known phosphonate biosynthetic
pathways, the second step is an irreversible decarboxylation of
phosphonopyruvate, which provides a thermodynamic driving
force to overcome the unfavorable initial step (Figure 1B). Sur-
prisingly, there is no recognizable homolog of phosphonopyru-
vate decarboxylase in the FR900098 gene cluster. A clue to
the fate of phosphonopyruvate is suggested by the presence
of three putative ORFs (frbA, frbB, and frbE; Table S1 and
Figure 3A) that are related to genes encoding enzymes in the
TCA cycle. A fourth (frbC) is homologous to homocitrate syn-
thase, which catalyzes an acetyl-CoA condensation similar to
that catalyzed by citrate synthase. Considering that phosphono-
pyruvate is a structural analog of oxaloacetate, we proposed that
the initial steps in biosynthesis of FR900098 parallel the TCA cy-
cle (Figure 3B). Thus, the thermodynamically favorable reactions
catalyzed by the homocitrate synthase and isocitrate dehydro-
genase homologs would provide the necessary thermodynamic
driving force. Hemmi et al. (1982) have previously suggested that
such a pathwaywould be feasible, and there is a precedent in the
bialaphos biosynthetic pathway in which phosphinopyruvate is
converted to the phosphinic acid analog of a-ketoglutarate
(aKG) by an analogous series of reactions (reviewed by Seto
and Kuzuyama, 1999).
To test the prediction that frbC and frbD encode phosphono-
methylmalate synthase and PEP mutase, respectively, recombi-
nant FrbC and FrbD were purified and assayed. Using an in vitro
assay based on a method commonly used to assay citrateier Ltd All rights reserved
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phosphonopyruvate in the presence of FrbC (Figure 4A), sug-
gesting that FrbC catalyzes condensation of the two molecules
driven by CoA thioester hydrolysis. We could further detect
CoASH formation starting from PEP and acetyl-CoA if both
FrbC and FrbD were present, confirming that FrbD is a PEP mu-
tase. 31P-NMR analysis of the reaction products revealed the
presence of a new phosphonic acid (data not shown), which
was confirmed to be 2-phosphonomethylmalate by LCMS
(Figure 4B).
The product of the three TCA cycle analog reactions, 2-oxo-4-
phosphonobutyrate, would be a phosphonate analog of aKG,
which could be converted into 3-aminopropylphosphonate by
consecutive amination and decarboxylation reactions. FrbH is
a homolog of PLP-dependent enzymes that are known to cata-
lyze both reaction types (e.g., histidinol phosphate aminotrans-
ferase and threonine phosphate decarboxylase) and could be
involved in either reaction.
To complete the biosynthesis of FR900098, the amino group
of 3-aminopropylphosphonate would need to be both acetylated
and hydroxylated. Because we detect N-acetyl-3-amino-
phosphonate and not N-hydroxy-3-aminophosphonate by
LCMS of the heterologous producer, we suggest the order is
acetylation followed by hydroxylation. FrbF shows high identity
to N-acetyltransferases and likely performs that reaction here.
Figure 2. Evidence for the Heterologous
Production of FR900098
(A) Detection of FR900098 by enzymatic assay.
Culture supernatant from the nonproducing S. liv-
idans parent strain (B) does not affect the reaction
catalyzed by E. coli DXR, as measured by observ-
ing the decrease in absorbance at 340 nm that re-
sults from oxidation of NADPH during the reaction.
Culture supernatant from S. lividans 4G7 (C) re-
sults in complete inhibition. The initial absorbance
has been normalized to 1 for both reactions for
ease of comparison.
(B) Detection of FR900098 by a phosphonate-spe-
cific bioassay. The phosphonate-sensitive E. coli
indicator strain WM6242 was assayed either unin-
duced (top) or induced (bottom) allowing for de-
tection of phosphonate-containing antibiotics.
Disks labeled 1 were soaked with authentic
FR900098 (50 mg/ml). Disks labeled 2were soaked
with supernatant from S. lividans 4G7. Disks la-
beled 3 were soaked with supernatant from the
parent S. lividans strain without a cosmid.
(C) 31P-NMR spectra of commercial FR900098
(left), culture supernatant from S. lividans 4G7
(center), and the same culture supernatant after
addition of commercial FR900098 (right).
(D) Selected ion chromatogram for FR900098 ± 2
ppm from an injection of culture supernatant with
summed mass spectrum (inset).
The identity of the enzyme responsible
for the subsequent hydroxylation reac-
tion is less clear. FrbJ is homologous to
aKG-dependent dioxygenases, a class
of enzymes that may be capable of N-hy-
droxylation, but catalysis of that type of
reaction by an enzyme of this class is without precedent.We pro-
pose no role for FrbG, which shows only very weak homology to
the small subunit of glutamate synthase. More definitive assign-
ment of the function of these enzymes will have to await in vitro
biochemical and in vivo genetic experiments.
Although dxrB is not required for production of FR900098, its
presence near the biosynthetic genes suggests a role in self-re-
sistance. The use of resistant forms of target enzymes has been
observed in other organisms. For example, a cycloserine-pro-
ducingS. lavendulae strain has been shown to also produce a cy-
closerine-resistant variant of alanine racemase, the target of that
inhibitor (Noda et al., 2004). We are currently investigating
whether the DXR encoded within the FR900098 cluster is indeed
resistant to FR900098.
Because we propose a role for the dxrB gene in self-resis-
tance, we have tentatively defined the FR900098 biosynthetic
gene cluster as comprising the entire region from frbA to dxrB,
although the frbA-H fragment alone is sufficient for production
of FR900098 in S. lividans.
SIGNIFICANCE
Our data suggest that the pathway for biosynthesis of this
antibiotic may have evolved from the tricarboxylic acid
cycle of central metabolism and utilizes an unusualChemistry & Biology 15, 765–770, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 767
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phonate biosynthetic pathways. Heterologous production
of FR900098 is possible using the identified genes, allowing
for creation of engineered strains that greatly overproduce
the antibiotic. Our proposed FR900098 biosynthetic pathway
includes two potent bioactive compounds as intermediates:
2-amino-4-phosphonobutyrate and 3-aminopropylphospo-
nate, which are known mimics of the major neurotransmit-
ters glutamate and g-aminobutyrate, respectively (Jane,
2000). Thus in addition to the biosynthesis of the antimalarial
compound FR900098, elucidation of this pathway in S. rubel-
lomurinus has uncovered a biosynthetic route to these two
well-known neuroactive compounds.
EXPERIMENTAL PROCEDURES
Cloning of the FR900098 Gene Cluster from S. rubellomurinus
S. rubellomurinus strain 5818 (ATCC 31215) was provided by the Fujisawa
Pharmaceutical (Osaka, Japan). S. lividans 66 was obtained from the USDA
Agricultural Research Service Culture Collection (Peoria, IL). See Supplemen-
tal Data for details on the strains and plasmids (Figure S2) used for cloning. The
PEP mutase gene in S. rubellomurinus was identified by PCR amplification
with degenerate primers (see Supplemental Data), which were designed using
CODEHOP (Rose et al., 1998) based on known PEP mutase sequences. Spe-
cific primers were designed to the S. rubellomurinus PEP mutase gene based
on the sequence of the amplification product. A genomic library of S. rubello-
murinus was prepared using genomic DNA obtained by a modification of the
method of Kieser et al. (2000) and is described in detail in the Supplemental
Data. This genomic DNA was partially digested to yield fragments of 20–60
kb, which were then ligated into pJK050. E. coli WM3118 cells were trans-
fected with the resulting fosmids. The E. coli library was screened by PCR
for clones containing the PEP mutase sequence. To add the functions neces-
sary for transfer and integration into S. lividans, the purified fosmids were indi-
Figure 3. The FR900098 Biosynthetic Gene
Cluster
(A) The arrangement of the FR900098 biosynthetic
genes. The end points of largest deletions that do
not eliminate antibiotic production (D126 and
D191) and smallest deletions that do (D061 and
D136) are also shown. D126 ends 117 bp before
the end of frbA, D191 removes 2233 of 2660 bp
of frbA, D136 removes 934 of 1886 bp of frbH,
and D191 removes 51 of 1886 bp of frbH. The re-
gion from frbA to frbH is sufficient for production of
FR900098 in the heterologous host S. lividans.
(B) The proposed biosynthetic pathway for
FR900098. The assignment of ORFs to chemical
steps is based on the proposed functions as de-
duced fromsequencecomparisons. Intermediates
in the production of FR900098: I, phosphoenolpyr-
uvate; II, 3-phosphonopyruvate; III, 2-phosphono-





vidually recombined in vitro with pAE4 using BP
clonase according to the manufacturer’s instruc-
tions. Fosmid:pAE4 cointegrants were isolated af-
ter transformation of E. coli DH5a and subse-
quently moved into the conjugal donor strain
E. coli WM3608 (Blodgett et al., 2005) for transfer to S. lividans 66. Conjugal
transfer was performed as described by Martinez et al. (2004) with modifica-
tions as detailed in the Supplemental Data.
Heterologous Expression of the FR900098 Gene
Cluster in S. lividans
To check for production of FR900098, S. lividans 4G7 was plated on Hickey-
Tresner agar (Kieser et al., 2000) or ISP4. After 4 days, the agar-solidified me-
dium was liquefied by freezing and subsequent thawing, and the liquid portion
was decanted from the remaining agar residue. To determine the presence or
absence of FR900098 in this supernatant, 5 ml was added to a DXR enzyme re-
action, and the reaction rate was compared with a control with 5 ml of super-
natant from a nonproducing strain. Purified recombinant E. coli DXR used in
the assays was prepared as described in the Supplemental Data.
The biosassay strain E. coli WM6242, which expresses the phosphonate
uptake system encoded by phnCDE under the control of a Ptac promoter
was constructed and used as described in Supplemental Data. Filter discs
(6 mm) were impregnated with 9 ml of the test solutions and placed on the sur-
face of the solidified plates. The bioassay plates were incubated for 12 h, and
the size of the growth inhibition zone scored. To confirm the heterologous pro-
duction of FR900098, inhibition zones from S. lividans 4G7 culture supernatant
were compared with supernatant from the S. lividans parent strain and a solu-
tion of authentic FR900098 (50 mg/ml).
For 31P-NMR detection of FR900098, culture supernatant was concentrated
approximately 10-fold by evaporation. 31P-NMR spectra were externally refer-
enced to an 85% phosphoric acid standard set at 0 ppm. To confirm that the
observed peak corresponded to FR900098, an authentic sample of FR900098
was added to a concentration of 100 mg/mL, and the spectrum of the sample
was recorded again under identical conditions. For the mass spectrometric
detection of FR900098 and N-acetyl-3-aminophosphonate, samples were
prepared, separated on an Atlantis HILIC silica column, and infused into
a LTQ-FT mass spectrometer for negative ion FTMS detection as described
in detail in Supplemental Data. The identities of FR900098 andN-acetyl-3-ami-
nophosphonate were confirmed by both accurate mass analysis (<2 ppm) and
tandem MS fragmentation.768 Chemistry & Biology 15, 765–770, August 25, 2008 ª2008 Elsevier Ltd All rights reserved
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To sequence fosmid 4G7, a library of transposon insertions was generated us-
ing the mini-Mu transposon encoded in pAE5 and sequenced as described in
Supplemental Data. Potential open-reading frames were identified using
BLAST analysis (Altschul et al., 1990), GeneMark (Borodovsky and McIninch,
1993), and visual inspection. To determine the portion of the cosmid required
for antibiotic production, various deletions were made by site-specific recom-
bination between frt or loxP sites present adjacent to the cloning site of the fos-
mid vector and the matching site on selected mini-Mu transposon insertions.
These deletions remove all DNA between the site of the transposon insertion
(chosen based on the DNA sequencing results) and the cloning junction in fos-
mid 4G7. The resulting recombinant plasmids were integrated into S. lividans
66, and exconjugants were assayed for the ability to produce FR900098 using
the E. coli DXR inhibition assay and by mass spectrometry. The complete
Figure 4. Biochemical Evidence for 2-Phosphonomethylmalate as
an Intermediate in the FR900098 Biosynthetic Pathway
(A) In vitro CoASH formation from acetyl-CoA and phosphonopyruvate or
phosphoenolpyruvate depends on the presence of FrbC or FrbC + FrbD re-
spectively.
(B) Selected ion chromatogram for 2-phosphonomethylmalate ± 1 ppm from
an injection of reaction mixture (20 mL) with summed mass spectrum (inset).
(C) High-resolution MS2 spectrum for the precursor ion at negative m/z 227
showing the predictable losses of water and the added acetyl group.Chemistry & Biology 15, 76sequence of this 14.4 kb region has been deposited in GenBank with acces-
sion number DQ267750.
Determination of Enzymatic Activity of FrcB and FrbD
TheN-His6-tagged FrbC and FrbD proteins, purified after recombinant expres-
sion of genes, were obtained by PCR amplification from the fosmid 4G7 as de-
scribed in Supplemental Data. Phosphonomethylmalate synthase activity was
assayed by tracking CoASH formation in a reaction similar to that used for
phosphinomethylmalate synthase (Shimotohno et al., 1988) starting from ei-
ther phosphoenolpyruvate or phosphonopyruvate and using FrbD + FrbC or
FrbC, respectively. Phosphonomethylmalate formation was confirmed using
LCMS by both accurate mass analysis (<2 ppm) and tandem MS fragmenta-
tion (see Supplemental Data for a detailed description of the enzyme assay
conditions and analytical methods).
ACCESSION NUMBERS
The complete sequence of this 14.4 kb region has been deposited in GenBank
with accession number DQ267750.
SUPPLEMENTAL DATA
Supplemental Data include two figures, one table, Supplemental Experimental
Procedures, and Supplemental References, and can be found with this article
online at http://www.chembiol.com/cgi/content/full/15/8/765/DC1/.
ACKNOWLEDGMENTS
We thank the Fujisawa Company for providing S. rubellomurinus 5818, Adam
Guss for constructing strain WM3118, and Jun Kai Zhang for constructing
plasmid pJK050. We are also grateful to Deborah Dunaway-Mariano for pro-
viding phosphonopyruvate, andChrisWright and Laura Guest of the UIUCBio-
technology Center for their help with sequencing. This work was supported by
NIGMSGrants GM059334B toW.W.M., GM077596 to H.Z., and GM077596 to
W.W.M., W.A.V., H.M.Z., and N.L.K.; U.S. National Institutes of Health Chem-
ical Biology Interface Training Grant 5T32 GM070421; and a National Science
Foundation postdoctoral fellowship to A.C.E. Support was also provided by
the Institute for Genomic Biology Fellows Program (to B.M.G.).
Received: March 21, 2008
Revised: June 30, 2008
Accepted: July 8, 2008
Published: August 22, 2008
REFERENCES
Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic
local alignment search tool. J. Mol. Biol. 215, 403–410.
Barry, R.J., Bowman, E., McQueney, M., and Dunaway-Mariano, D. (1988).
Elucidation of the 2-aminoethylphosphonate biosynthetic pathway in Tetrahy-
mena pyriformis. Biochem. Biophys. Res. Commun. 153, 177–182.
Blodgett, J.A., Zhang, J.K., and Metcalf, W.W. (2005). Molecular cloning, se-
quence analysis, and heterologous expression of the phosphinothricin tripep-
tide biosynthetic gene cluster from Streptomyces viridochromogenes DSM
40736. Antimicrob. Agents Chemother. 49, 230–240.
Borodovsky, M., and McIninch, J. (1993). GeneMark: parallel gene recognition
for both DNA strands. Comput. Chem. 17, 123–133.
Bowman, E.D., McQueney, M.S., Scholten, J.D., and Dunaway-Mariano, D.
(1990). Purification and characterization of the Tetrahymena pyriformis P-C
bond forming enzyme phosphoenolpyruvate phosphomutase. Biochemistry
29, 7059–7063.
Hemmi, K., Takeno, H., Hashimoto, M., and Kamiya, T. (1982). Studies on
phosphonic acid antibiotics. IV. Synthesis and antibacterial activity of analogs
of 3-(N-acetyl-N-hydroxyamino)-propylphosphonic acid (FR-900098). Chem.
Pharm. Bull. (Tokyo) 30, 111–118.5–770, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 769
Chemistry & Biology
FR900098 BiosynthesisHidaka, T., Goda, M., Kuzuyama, T., Takei, N., Hidaka, M., and Seto, H. (1995).
Cloning and nucleotide sequence of fosfomycin biosynthetic genes of Strep-
tomyces wedmorensis. Mol. Gen. Genet. 249, 274–280.
Hidaka, T., Mori, M., Imai, S., Hara, O., Nagaoka, K., and Seto, H. (1989). Stud-
ies on the biosynthesis of bialaphos (SF-1293). 9. Biochemical mechanism of
C-P bond formation in bialaphos: discovery of phosphoenolpyruvate phos-
phomutase which catalyzes the formation of phosphonopyruvate from phos-
phoenolpyruvate. J. Antibiot. (Tokyo) 42, 491–494.
Jane, D.E. (2000). Neuroactive aminophosphonic and aminophosphinic acid
derivatives. In Aminophosphonic and Aminophosphinic Acids, V.P. Kukjar
and H.R. Hudson, eds. (New York: John Wiley & Sons), pp. 483–535.
Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C.,
Hintz, M., Turbachova, I., Eberl, M., Zeidler, J., Lichtenthaler, H.K., et al.
(1999). Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis
as antimalarial drugs. Science 285, 1573–1576.
Kieser, T., Bibb, M.J., Buttner, M.J., Chater, K.F., and Hopwood, D.A. (2000).
Practical Streptomyces Genetics (Norwich, UK: John Innes Foundation).
Kuzuyama, T., Shimizu, T., Takahashi, S., and Seto, H. (1998). Fosmidomycin,
a specific inhibitor of 1-deoxy-d-xylulose 5-phosphate reductoisomerase in
the nonmevalonate pathway for terpenoid biosynthesis. Tetrahedron. Lett.
39, 7913–7916.
Martinez, A., Kolvek, S.J., Yip, C.L., Hopke, J., Brown, K.A., MacNeil, I.A., and
Osburne, M.S. (2004). Genetically modified bacterial strains and novel bacte-
rial artificial chromosome shuttle vectors for constructing environmental librar-
ies and detecting heterologous natural products in multiple expression hosts.
Appl. Environ. Microbiol. 70, 2452–2463.
Noda, M., Kawahara, Y., Ichikawa, A., Matoba, Y., Matsuo, H., Lee, D.G., Ku-
magai, T., and Sugiyama,M. (2004). Self-protectionmechanism in D-cycloser-
ine-producing Streptomyces lavendulae. Gene cloning, characterization, and
kinetics of its alanine racemase and D-alanyl-D-alanine ligase, which are target
enzymes of D-cycloserine. J. Biol. Chem. 279, 46143–46152.770 Chemistry & Biology 15, 765–770, August 25, 2008 ª2008 ElsevOkuhara, M., Kuroda, Y., Goto, T., Okamoto, M., Terano, H., Kohsaka, M.,
Aoki, H., and Imanaka, H. (1980). Studies on new phosphonic acid antibiotics.
I. FR-900098, isolation and characterization. J. Antibiot. (Tokyo) 33, 13–17.
Rohmer, M. (1999). The discovery of a mevalonate-independent pathway for
isoprenoid biosynthesis in bacteria, algae and higher plants. Nat. Prod. Rep.
16, 565–574.
Rose, T.M., Schultz, E.R., Henikoff, J.G., Pietrokovski, S., McCallum, C.M.,
and Henikoff, S. (1998). Consensus-degenerate hybrid oligonucleotide
primers for amplification of distantly related sequences. Nucleic Acids Res.
26, 1628–1635.
Schlitzer, M. (2007). Malaria chemotherapeutics part 1: history of antimalarial
drug development, currently used therapeutics, and drugs in clinical develop-
ment. ChemMedChem 2, 944–986.
Schwartz, D., Berger, S., Heinzelmann, E., Muschko, K., Welzel, K., andWohl-
leben, W. (2004). Biosynthetic gene cluster of the herbicide phosphinothricin
tripeptide from Streptomyces viridochromogenes Tu494. Appl. Environ.
Microbiol. 70, 7093–7102.
Seidel, H.M., Freeman, S., Seto, H., and Knowles, J.R. (1988). Phosphonate
biosynthesis: isolation of the enzyme responsible for the formation of a car-
bon-phosphorus bond. Nature 335, 457–458.
Seto, H., and Kuzuyama, T. (1999). Bioactive natural products with carbon-
phosphorus bonds and their biosynthesis. Nat. Prod. Rep. 16, 589–596.
Shimotohno, K.W., Seto, H., Otake, N., Imai, S., and Murakami, T. (1988).
Studies on the biosynthesis of bialaphos (Sf-1293). 8. Purification and charac-
terization of 2-phosphinomethylmalic acid synthase from Streptomyces
Hygroscopicus Sf-1293. J. Antibiot. (Tokyo) 41, 1057–1065.
Snow, R.W., Guerra, C.A., Noor, A.M., Myint, H.Y., and Hay, S.I. (2005). The
global distribution of clinical episodes of Plasmodium falciparum malaria.
Nature 434, 214–217.ier Ltd All rights reserved
